title: Duration of prophylaxis against fungal infection in kidney transplant recipients.
abstract: OBJECTIVE
  To compare the efficacy of 2 strategies that use nystatin to prevent thrush and Candida esophagitis in kidney transplant recipients.
  
  
  METHODS
  A retrospective chart review was conducted of adult kidney transplant recipients at our center, where the protocol for prophylaxis against fungal infection was changed in March 2013. Before the protocol change, kidney transplant recipients received nystatin for 1 month (before group) and after the change they received nystatin for the duration of admission (after group). The primary outcome measure was the incidence of thrush and Candida esophagitis within 3 months after transplant. Analyses were conducted on all kidney transplant recipients (intention to treat) and on only those kidney transplant recipients who received at least 1 dose of nystatin (modified intention to treat). Additional data collected included the duration of nystatin and immunosuppression regimens. The Student t test and Fisher exact test were used to calculate P values for continuous and categorical data.
  
  
  RESULTS
  A total of 84 kidney transplant recipients, 42 in each cohort, were included in the analysis. The groups did not differ significantly at baseline. Nystatin was administered for a mean of 29 days in the before group and 5.74 days in the after group. Overall, 3 kidney transplant recipients (4%), all from the after group, experienced an episode of thrush and no patients experienced Candida esophagitis. Two recipients who experienced thrush did not receive any nystatin.
  
  
  CONCLUSIONS
  Limiting the administration of nystatin to the duration of admission after transplant may be sufficient for prophylaxis of fungal infections in kidney transplant recipients.
authors.affiliation: Yale-New Haven Health System (CMG, RNF, SK, WSA, EMT), Yale University School of Medicine (RNF, SK, WSA), New Haven, Connecticut.
authors.forename: Christina M
authors.initials: CM
authors.lastname: Guerra
authors.affiliation: Yale-New Haven Health System (CMG, RNF, SK, WSA, EMT), Yale University School of Medicine (RNF, SK, WSA), New Haven, Connecticut.
authors.forename: Richard N
authors.initials: RN
authors.lastname: Formica
authors.affiliation: Yale-New Haven Health System (CMG, RNF, SK, WSA, EMT), Yale University School of Medicine (RNF, SK, WSA), New Haven, Connecticut.
authors.forename: Sanjay
authors.initials: S
authors.lastname: Kulkarni
authors.affiliation: Yale-New Haven Health System (CMG, RNF, SK, WSA, EMT), Yale University School of Medicine (RNF, SK, WSA), New Haven, Connecticut.
authors.forename: William S
authors.initials: WS
authors.lastname: Asch
authors.affiliation: Yale-New Haven Health System (CMG, RNF, SK, WSA, EMT), Yale University School of Medicine (RNF, SK, WSA), New Haven, Connecticut.
authors.forename: Eric M
authors.initials: EM
authors.lastname: Tichy
mesh_terms: D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy* / Q000209:etiology*; D002180:Candidiasis, Oral / Q000188:drug therapy* / Q000209:etiology*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009761:Nystatin / Q000627:therapeutic use*; D012189:Retrospective Studies; D013997:Time Factors; D066027:Transplant Recipients
chemical_list: D000935:Antifungal Agents; D009761:Nystatin